FeesSafety
Pluang+

Genius Group advances ASX dual listing and expands AI data center project to Australia

Market News
04 Nov 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
Genius Group advances ASX dual listing and expands AI data center project to Australia

Genius Group Limited has approved its formal application for a dual listing on the Australian Securities Exchange (ASX) after achieving a positive net working capital surplus and reducing debt. The company also plans to expand its GENIUSpark AI-powered education and data center initiative from Canada to Australia, addressing growing AI infrastructure demand and workforce skill shortages there. This dual listing aims to broaden the investor base and support growth opportunities in the Asia-Pacific region, including future developments in Southeast Asia and Indonesia. The ASX listing is pending regulatory approval, with updates expected as the process progresses.

Genius Group's ASX dual listing and AI data center expansion plans provide context for technology sector trends on Pluang. As of Nov 04, 2026 19:11 WIB, out of 150 priced Technology-sector US stocks tradable on Pluang, 82 rose and 62 fell. Notable movers include Skyworks Solutions Inc (SWKS) down 13.99% with 100% sell orders, Kyndryl Holdings Inc (KD) up 11.44%, and Block Inc (XYZ) up 10.49% but with 100% sell orders.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
25 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
25 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
25 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
25 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
25 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App